Abstract:The 2019-2020 winter was marked by the emergence of a new coronavirus (SARS-CoV-2) related disease (COVID-19), which started in Wuhan, China. Its high human-to-human transmission ability led to a worldwide spread within few weeks and has caused substantial human loss. Mechanical antiviral control approach, drug repositioning, and use of COVID-19 convalescent plasmas (CPs) were the first line strategies utilized to mitigate the viral spread, yet insufficient. The urgent need to contain this deadly pandemic has led searchers and pharmaceutical companies to develop vaccines. However, not all vaccines manufactured are safe. Besides, an alternative and effective treatment option for such an infectious disease would include pure anti-viral neutralizing monoclonal antibodies (NmAbs), which can block the virus at specific molecular targets from entering cells by inhibiting virus-cell structural complex formation, with more safety and efficiency than the CP. Indeed, there is a lot of molecular evidence about the protector effect and the use of molecular feature-based NmAbs as promising therapeutics to contain COVID-19. Thus, from the scientific publication database screening, we here retrieved antibody-related papers and summarized the repertory of characterized NmAbs against SARS-CoV-2, their molecular neutralization mechanisms, and their immunotherapeutic pros and cons. About 500 anti-SARS-CoV-2 NmAbs, characterized through competitive binding assays and neutralization efficacy, were reported at the writing time (January 2021). All NmAbs bind respectively to SARS-CoV-2 S and exhibit high molecular neutralizing effects against wild-type and/or pseudotyped virus. Overall, we defined six NmAb groups blocking SARS-CoV-2 through different molecular neutralization mechanisms, from which five potential neutralization sites on SARS-CoV-2 S protein are described. Therefore, more efforts are needed to develop NmAbs-based cocktails to mitigate COVID-19.

Neutralizing Monoclonal Antibodies Present New Prospects to Treat SARS-CoV-2 Infections

Bispecific Antibodies Targeting Distinct Regions of the Spike Protein Potently Neutralize SARS-CoV-2 Variants of Concern

Neutralization of SARS-CoV-2 Infection by Antibodies Targeting Diverse Epitopes

Potent Molecular Feature-based Neutralizing Monoclonal Antibodies As Promising Therapeutics Against SARS-CoV-2 Infection

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Monoclonal antibody therapies in the management of SARS-CoV-2 infection

Monoclonal neutralizing antibodies against SARS-COV-2 S protein

Neutralizing monoclonal antibodies against highly pathogenic coronaviruses

Neutralizing monoclonal antibodies for treatment of COVID-19

A SARS-CoV-2 neutralizing antibody with exceptional spike binding coverage and optimized therapeutic potentials

Neutralizing Antibodies for the Prevention and Treatment of COVID-19

A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes

Status and Developing Strategies for Neutralizing Monoclonal Antibody Therapy in the Omicron Era of COVID-19

Opportunities and Challenges to the Use of Neutralizing Monoclonal Antibody Therapies for COVID-19

The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2

Human Monoclonal Antibodies Block the Binding of SARS-CoV-2 Spike Protein to Angiotensin Converting Enzyme 2 Receptor.

Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective.

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections

Human IgG Neutralizing Monoclonal Antibodies Block SARS-CoV-2 Infection

Human Monoclonal Antibodies: on the Menu of Targeted Therapeutics Against COVID-19